HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Intervention...
NRX Pharmaceuticals, Inc. (NRXP)
Company Research
Source: Yahoo! Finance
Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of Florida Stephen Durand , founder of Dura, to serve as Director of Clinic Growth for HOPE in Florida Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI Jan. 6, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced the planned acquisition of Dura Medical (Dura), under a non-binding Letter of Intent . Dura is expected to be the first Florida acquisition for HOPE and serve as a cornerstone for the Southeastern States. Dura is revenue generating and EBITDA positive with immediate expansion opportunity to Florida's East Coast and beyond. (PRNewsfoto/NRx Pharmaceuticals) Dura was founded in 2018 to offer a gold-standard, precision approach to treating mental health and chronic pain.
Show less
Read more
Impact Snapshot
Event Time:
NRXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXP alerts
High impacting NRX Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NRXP
News
- HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th AAcquire Media Monitor
- HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th APR Newswire
- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.MarketBeat
- HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical OperationsPR Newswire
- HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry ClinicsPR Newswire
NRXP
Earnings
- 11/14/24 - Beat
NRXP
Sec Filings
- 12/18/24 - Form 4
- 11/22/24 - Form 3
- 11/20/24 - Form 8-K
- NRXP's page on the SEC website